IMR Press / EJGO / Volume 23 / Issue 1 / pii/2002105

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. Case report

Show Less
1 Data Centre, Jules Bordet Institute, Brussels (Belgium)
2 Gynaecologic Surgery Department, Jules Bordet Institute, Brussels (Belgium)
3 Anatomopathologic Department, Jules Bordet Institute, Brussels (Belgium)
Eur. J. Gynaecol. Oncol. 2002, 23(1), 25–28;
Published: 10 February 2002

Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recom­mended. Transvaginal ultrasonography is a very sensitive test and therefore is often performed as a first-line screening test. We described a very atypical case of a high stage, high grade endometrial cancer associated with tamoxifen in a 64-year-old woman with a past history of breast cancer. This women was assessed yearly by ultrasonography and Pap smear. The cancer developed on a very thin endometrium and transvaginal ultrasonography failed to detect it. The patient remained asymptomatic up to the diagnosis. Normal endometrial cells in the Pap smear test were the only signs associated with this cancer. Surveillance strategies and significance of endometrial cells on the Pap smear are reviewed. In conclusion, TYUS can fail to detect cancers if the endometrial lining is not enlarged. In case of normal endometrial cells in the Pap smear, a careful evaluation should be performed.

Uterine neoplasms
Surveillance strategy
Pap smear
Transvaginal ultrasonography
Back to top